• Trump administration issues executive order to reform pharmacy benefit managers (PBMs) and increase drug price transparency.
  • The order directs HHS to implement measures including Medicare negotiation, drug importation, and lower insulin costs.
  • Industry pushback expected as reforms could disrupt traditional PBM profit models while benefiting patients.

Trump Takes Aim at Drug Pricing Middlemen

President Donald Trump signed an executive order on April 15 targeting pharmacy benefit managers in his latest effort to reduce prescription drug costs. The order instructs the Department of Health and Human Services to implement policies that would increase transparency around drug pricing and rebates while potentially restructuring how PBMs operate within the pharmaceutical supply chain.

Among its key provisions, the order seeks to pass government-mandated discounts directly to patients rather than allowing PBMs to retain portions of these savings—a practice that has drawn increasing scrutiny. It also renews efforts to allow importation of lower-cost drugs and specifically addresses affordability of insulin and epinephrine for low-income patients.

"We're taking direct action to bring down prescription costs by cutting out the middlemen who've been profiting at the expense of American patients," a senior administration official said, speaking on condition of anonymity ahead of the formal announcement. The White House expects the measures could save consumers billions annually if fully implemented.

Market Reactions and Implementation Challenges

While patient advocacy groups have welcomed the move, pharmacy benefit managers and some pharmaceutical companies are expected to resist aspects of the order. Previous attempts to reform PBMs during Trump's first term faced significant industry opposition and legal challenges, with many proposals never fully implemented.

The National Association of Chain Drug Stores has already called for further PBM reforms, suggesting the order may not go far enough for some stakeholders. Meanwhile, analysts note that the administration's decision to work with rather than repeal the Inflation Reduction Act's Medicare drug price negotiation provisions represents a pragmatic shift in strategy.

Implementation timelines remain unclear, with HHS given broad authority to develop specific regulations. The order could face court challenges, particularly around drug importation provisions that have been blocked in previous iterations. Market participants will be watching closely to see whether this attempt succeeds where others have stalled.